XNYS
HUM
Market cap47bUSD
Jul 09, Last price
397.76USD
1D
0.37%
1Q
107.00%
Jan 2017
94.95%
Name
Humana Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Humana Inc., along with its various subsidiaries, functions as a prominent health and well-being organization exclusively within the United States. Its operations are strategically divided into three key divisions: Retail, Group and Specialty, and Healthcare Services. The company provides a range of medical and supplemental benefit plans directly to individual consumers. Humana actively participates in government-sponsored health initiatives, holding contracts with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LINET) prescription drug plan. Additionally, it partners with numerous states to deliver benefits under Medicaid, dual eligible programs, and long-term support services. Beyond this, it extends commercial fully insured medical and specialized health coverage, encompassing dental, vision, and other ancillary health benefits. Humana also furnishes administrative services only (ASO) products to both individuals and employer groups, and supports military personnel through programs like the TRICARE T2017 East Region contract. Furthermore, its service portfolio includes pharmacy solutions, provider support, and comprehensive home-based care (such as home health), catering to both its health plan enrollees and external clients. As of December 31, 2021, Humana's member base comprised roughly 17 million individuals enrolled in medical benefit plans, alongside approximately 5 million participating in specialty offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||